Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041672 | 0.83 | CTSK (0.47) | KMT2AMEN1MMP2GAA | |
| SCHEMBL4073951 | 0.80 | KMT2A (0.50) | KMT2AMEN1EPHX2LMNAMAPT | |
| SCHEMBL6093953 | 0.78 | UTS2R (0.48) | KMT2AMEN1EPHX2LMNAGAA | |
| SCHEMBL4077783 | 0.78 | ATM (0.47) | EPHX2ALDH1A1PKM | |
| SCHEMBL14342651 | 0.78 | UTS2R (0.61) | — | |
| SCHEMBL14342647 | 0.76 | F10 (0.45) | KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL4120462 | 0.76 | LMNA (0.70) | KMT2AMEN1EPHX2LMNAMAPT | |
| SCHEMBL6739733 | 0.75 | UTS2R (0.47) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL6404949 | 0.74 | CTSK (0.50) | EPHX2 | |
| SCHEMBL5098745 | 0.74 | CTSK (0.47) | EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796793-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | claimed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | claimed |
| EP-1796793-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006029154-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | claimed |
| EP-1796793-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20070293477-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2007-12-20 | — | — | US | disclosed |
| EP-1796793-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029154-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293477-A1 | Novel Compounds | HRH4, TRPV4, TRPC4 | KMT2A 3942/4885MEN1 2106/4885EPHX2 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.